Ki Park, MD
Dr. Ki Park is a Clinical Assistant Professor of Medicine in Interventional Cardiology. She received a BS degree in microbiology at the University of Florida. She also completed her Internal Medicine Residency, General Cardiology Fellowship and Interventional Cardiology Fellowship at the University of Florida. In addition, during her fellowship training she completed a Cardiovascular Cell Therapy Research Network (CCTRN) Fellowship and also earned a MS in Translational Science through the APPCI program. In 2010, she received the UF Department of Medicine Excellence in Research Award as well as the American Heart Association Women in Cardiology Trainee Award for Excellence.
|BS||University of Florida||Microbiology|
|MD||University of Florida||Medicine|
|Residency||University of Florida||Internal Medicine|
|Research Fellow||University of Florida||Cardiovascular Medicine|
|MS||University of Florida||Translational Science|
|Fellowship||University of Florida||Cardiovascular Medicine|
- Research interests include studying invasive methods of evaluating ventricular function and delivering biologics as part of cell therapy for cardiovascular diseases
- Percutaneous coronary intervention
- Transradial catheterization
- Women’s cardiovascular health
- Park K, Wei J, Minissian M, Bairey Merz CN, Pepine CJ. Adverse pregnancy conditions, infertility, and future cardiovascular risk: implications for mother and child. Cardiovasc Drugs Ther. 2015 Jun 3. [Epub ahead of print].
- Park KE, Pepine CJ. Assessing cardiovascular risk in women: looking beyond traditional risk factors. Trends Cardiovasc Med. 2015;25(2):152-3.
- Petersen JW, Winchester DE, Park K, Szady AD, Della Rocca DG, Ahmed M, Tassin H, Qi Y, Pepine CJ. A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network. Regen Med. 2014;9(6):793-7.
- Park KE, Huo T, Muller KE, Aranda JM, Hill JA, Anderson RD. Drug-eluting stents may not reduce target lesion revascularization in cardiac allograft vasculopathy. J Interv Cardiol. 2014;27(1):80-5.
- Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25-32.
- Park KE, Moyé LA, Henry TD, Perin EC, Sayre SL, Bettencourt J, Vojvodic RW, Olson RE, Pepine CJ; CCTRN. Implementation of cardiovascular cell therapy network trials: challenges, innovation and lessons learned from experience in the CCTRN. Expert Rev Cardiovasc Ther. 2013;11(11):1495-502.
- Park K, Bavry AA. Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events. Cleve Clin J Med. 2013;80(5):318-26.
- Park K, Qin Y, Bavry AA. Nonsteroidal anti-inflammatory drugs and their effects in the elderly. Aging Health. 2012;8(2):167-77.
- Winchester DE, Brearley WD, Wen X, Park KE, Bavry AA. Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines. Clin Cardiol. 2012;35(2):93-100.
- Sequeira C, Park K, Pepine CJ, Cogle CR. Stem and progenitor cell therapies for cardiovascular disease. J Cell Sci Ther. 2011;S1:001. doi:10.4172/2157-7013.S1-001
- Park KE, Pepine CJ. Microvascular dysfunction: What have we learned from WISE? Expert Rev Cardiovasc Ther. 2011;9(12):1491-4.
- Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J Am Coll Cardiol. 2011;57(10):1190-9.
- Park KE, Pepine CJ. Bone marrow-derived cells and hypertension. Expert Rev Cardiovasc Ther. 2010;8(8):1139-48.
- Park KE, Pepine CJ. Pathophysiologic mechanisms linking impaired cardiovascular health and neurologic dysfunction: the year in review. Cleve Clin J Med. 2010;77 Suppl 3:S40-5.